Evidence map›Paper›PMID 41053018›Full record

ArticleCell death & disease2025

Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)

Maria Vidal-Sabanés, Núria Bonifaci, Raúl Navaridas, Joaquim Egea, Mario Encinas, Ruth Rodriguez-Barrueco, Jose M Silva, Xavier Matias-Guiu, David Llobet-Navas, Xavier Dolcet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. miR-424(322)Cell death & disease · 2026
    Article
  4. Article
  5. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Vidal-SabanésDevelopmental and Oncogenic Signaling Group, Departament de Ciències Mèdiques Bàsqieus/Medicina Experimental, Universitat de Lleida. Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain.
Núria BonifaciMolecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Raúl NavaridasHerbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0003-1622-5311
Joaquim EgeaDevelopmental and Oncogenic Signaling Group, Departament de Ciències Mèdiques Bàsqieus/Medicina Experimental, Universitat de Lleida. Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain.
Mario EncinasDevelopmental and Oncogenic Signaling Group, Departament de Ciències Mèdiques Bàsqieus/Medicina Experimental, Universitat de Lleida. Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain.
Ruth Rodriguez-BarruecoMolecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4925-8865
Jose M SilvaDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Xavier Matias-GuiuCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, (ISCIII), Madrid, Spain.
David Llobet-NavasMolecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. dllobet@idibell.cat.ORCID http://orcid.org/0000-0003-1443-7003
Xavier DolcetDevelopmental and Oncogenic Signaling Group, Departament de Ciències Mèdiques Bàsqieus/Medicina Experimental, Universitat de Lleida. Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain. xavi.dolcet@udl.cat.ORCID http://orcid.org/0000-0003-1921-0449

Funding

Ministerio de Educación, Cultura y Deporte (Ministry of Education, Culture and Sports, Spain) PID2019-104734RB-I00Ministerio de Educación, Cultura y Deporte (Ministry of Education, Culture and Sports, Spain) PID2022-141220OB-I00Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CB16/1200231Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI24/01255
6 · The paper itself

Abstract

Endometrial cancer is the most frequent type of cancer in the female reproductive tract. Loss-of-function alterations in PTEN, leading to enhanced PI3K/AKT activation, are among the most frequent molecular alterations in endometrial cancer. Increased PI3K/AKT signaling resulting from PTEN loss promotes cellular proliferation and confers resistance to TGFβ-mediated apoptosis, a key regulator of endometrial homeostasis. In this study, we have analyzed the role of miRNAs in driving these altered cellular responses. A comprehensive transcriptomic analysis of miRNA expression revealed the upregulation of several miRNAs caused by PTEN deficiency and/or TGFβ stimulation. The miR-424(322)

Indexed as

Endometrial NeoplasmsMicroRNAsPTEN PhosphohydrolaseAnimalsApoptosisCell ProliferationCells, CulturedDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceSignal TransductionTransforming Growth Factor betaMicroRNAsMIRN322 microRNA, mouseMIRN424 microRNA, mouseMirn503 microRNA, mousePTEN PhosphohydrolasePten protein, mouseTransforming Growth Factor beta

Identifiers

PMID41053018
PMCPMC12501053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.